Zoetis (ZTS): analysis in plain words
Is Zoetis cheap or expensive? How it makes money, whether it grows and its risks, explained in plain words and with its official accounts.
Zoetis (ZTS) is listed on the NYSE and we classify it in healthcare and pharma. Below are its key dated figures, how it makes money, how it compares with its sector, what works for and against Zoetis according to those figures, and the questions people ask most about the stock. No buy or sell tips.
Zoetis (ZTS) key figures as of November 4, 2026
| Figure | Value | What it measures |
|---|---|---|
| Share price | $89.20 | Last price on November 4, 2026 |
| P/E ratio (TTM) | 14.7x | Price over earnings per share |
| Revenue growth | -0.2% | Latest quarter vs the same quarter a year earlier |
| Net margin (TTM) | 27.7% | Profit for every 100 of sales |
| Net debt / EBITDA | 1.9x | Years of operating profit to repay debt |
| Dividend yield | 2.55% | Annual dividend over price |
| Market cap | $36.9 billion | What the stock market values it at |
The Zoetis figures come from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026. Any ZTS figure that is not available shows as N/A: we do not estimate it.
How Zoetis makes money
Zoetis makes medicines, vaccines and diagnostics for animals. Companion animal products such as Simparica, Apoquel and Librela for dogs and cats bring in most of its sales, while livestock products treat cattle, pigs, poultry and fish. The company reports two segments: United States and International.
Over the last 12 months, Zoetis brought in revenue of $9.5 billion. For every 100 it sells, Zoetis keeps 71.7 after the direct cost of what it sells (gross margin) and 40.7 after all operating costs (operating margin). With 14,500 full-time employees, that is about $657,000 of revenue per employee.
Zoetis against its sector
To know whether a Zoetis figure is high or low you have to put it next to similar companies. This table compares Zoetis with the median of the 30 healthcare and pharma companies Fintols covers, with data as of November 4, 2026.
| Figure | Zoetis | healthcare and pharma median |
|---|---|---|
| P/E | 14.7x | 31.3x (30) |
| Revenue growth | -0.2% | +8.3% (33) |
| Net margin | 27.7% | 14.9% (33) |
| Dividend yield | 2.55% | 1.52% (33) |
| Net debt / EBITDA | 1.9x | 1.6x (31) |
In short, against the typical healthcare and pharma company, Zoetis trades on a lower P/E, grows more slowly and earns a wider margin. By size, Zoetis ranks number 27 of 28 healthcare and pharma companies quoted in USD on Fintols.
The bull case for Zoetis
These are the strengths in the Zoetis figures as of November 4, 2026:
- Its net margin over the last 12 months is 27.7% (sector median: 14.9%): Zoetis turns a large share of its sales into profit.
- On a P/E basis Zoetis trades cheaper than its sector: 14.7x its annual earnings, against 31.3x for the healthcare and pharma median (30 companies with data).
- Zoetis earns 64.9% a year on its shareholders' money (return on equity).
The main risk for Zoetis
Zoetis stock sits 33% below its 52-week high ($132.49): the market has cut its expectations, and it is worth understanding why first.
On top of that: zoetis sales fell 0.2% in the latest quarter against the same quarter a year earlier: if the decline drags on, profit usually follows.
And, like the rest of healthcare and pharma, Zoetis is exposed to a key drug losing patent protection or a clinical trial failing, plus government pressure on prices.
Frequently asked questions about Zoetis
Is it a good time to buy Zoetis stock?
Fintols does not tell you whether to buy or sell Zoetis, and nobody knows what the price will do tomorrow. What we can show you is where it stands today. As of November 4, 2026, Zoetis stock trades at $89.20, 33% below its 52-week high ($132.49) and 30% above its low ($68.77). Its P/E is 14.7x against a healthcare and pharma median of 31.3x, and 13.9x on the earnings analysts expect over the next 12 months. With Zoetis, as with any stock, timing matters less than understanding the business, investing for the long run and not betting everything on a single company.
Does Zoetis pay a dividend?
Yes. As of November 4, 2026, Zoetis pays $2.12 per share a year, which at today's price is a yield of 2.55%. It uses 34% of its profit to pay it, which leaves room to keep paying it if profit dips. The healthcare and pharma median on Fintols is 1.52%.
Is Zoetis stock expensive?
It depends on what you compare it with. On P/E, Zoetis trades at 14.7x its last 12 months of earnings: cheaper than the healthcare and pharma median (31.3x). Including its debt, Zoetis is valued at 10.3x its EBITDA (EV/EBITDA). A high P/E alone does not make Zoetis expensive: it can be justified if earnings grow fast, and a low one can reflect a business in trouble.
Who are Zoetis's competitors?
On Fintols we compare Zoetis with Cigna, Elevance Health and Regeneron, which are also in healthcare and pharma. As of November 4, 2026, Cigna is worth $80.7 billion and trades on a P/E of 12.6; Elevance Health is worth $94.2 billion and trades on a P/E of 18.4; Regeneron is worth $96.3 billion and trades on a P/E of 20.6. Each has a side-by-side comparison with Zoetis below.
Zoetis competitors
- Cigna (CI) analysis · Zoetis vs Cigna comparison
- Elevance Health (ELV) analysis · Zoetis vs Elevance Health comparison
- Regeneron (REGN) analysis · Zoetis vs Regeneron comparison
To understand Zoetis better
- DCF and WACC Explained: A Practical Valuation Guide
- P/E Ratio and EPS Explained: How to Read Them Without Traps
More companies like Zoetis: healthcare and pharma stocks and S&P 500 companies. Open the full ZTS analysis with its valuation and scenarios. Educational content about Zoetis, not investment advice.